Duloxetine Metabolism and Fibromyalgia

Launched by UNIVERSITY OF UTAH · Mar 4, 2025

Keywords

ClinConnect Summary

This clinical trial is studying how the body processes a medication called duloxetine, which is often used to help manage symptoms of fibromyalgia. Fibromyalgia can cause widespread pain, fatigue, and sleep problems, and while duloxetine works well for some people, others may find it less effective. The goal of the study is to learn more about how different genes affect how duloxetine works in the body and its impact on fibromyalgia symptoms.

To participate in this trial, individuals need to be at least 18 years old, have been diagnosed with fibromyalgia, and have been taking duloxetine at a dose of 60 mg daily for at least 8 weeks. Unfortunately, pregnant individuals and those with certain medical conditions, like kidney or liver issues, cannot participate. If you join the study, you will help researchers gather important information that could lead to better treatments for fibromyalgia in the future. The trial is not yet recruiting participants, so there will be more details available later.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults 18+
• • Meeting diagnostic criteria for Fibromyalgia
• • Patients taking Duloxetine 60 mg/day for at least 8 weeks
• Exclusion Criteria:
• • Pregnant patients per verbal confirmation
• • Patients that have a history of physician diagnosed kidney or liver disfunction or history of renal dialysis.
• • Patients requiring an interpreter to communicate
• • Patient's with progressive illnesses other than fibromyalgia that have a chronic pain and fatigue component (e.g., cancer patients receiving antineoplastic treatment, Parkinson's disease, Multiple Sclerosis).